Next Phase Newsletter

A pharmaceutical company based in Asia has annual sales of about $160 million with more than 600 employees. The firm’s current marketing portfolio are mostly made of branded products licensed in from overseas partners. For the R&D activity, the firm has several clinical pipelines in the area of CNS and oncology under clinical study in the US, Europe, and Korea. The firm is actively searching for innovative candidates and products around the world to incorporate into its pipeline. Additionally, the firm also seek promising biotech with innovative approach to add into its investment portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. The firm is also able to invest in a financing round, preferably series A or B. In terms of indications, the firm is interested in movement disorders, CNS, liver disease, and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in late non-clinical development stage as well as in early clinical development stage. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third-party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in USA with additional offices in China invests in early-stage life science ventures, from Seed to Series B, with Series A and Series B being the firm’s sweet spot. Typical size of investment ranges from $1-2M in seed stage companies, and $3-5M in venture round companies.  
The firm also has an advisory service that supports entrepreneurs to expand to the Chinese market, and the firm has multiple offices in China and needed expertise to support the entrepreneur’s vision. 

Currently, the firm is most interested in companies based in USA, Israel, and Western Europe, particularly companies in the Nordic region. 
 
The firm will consider therapeutics, medical devices, diagnostics, and life science tools. The firm is most interested in medical devices, and their interests include medtech and biotech combination products, novel methods of drug delivery, in vitro diagnostics (novel instruments and reagents), etc. The firm is interested in both 510K and PMA devices. Within therapeutics, the firm is more interested in clinical assets and typically do not look at pre-clinical companies unless the opportunity is compelling. Current main indication areas of interest for the firm are cardiovascular disease, oncology, and women’s health. 
 
The firm seeks to work with management teams who are passionate about their technology and dedicated to creating values for the larger community. Though the firm is able to support companies who are interested in entering the China market, having a China angle is not necessary for investment. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The strategic fund of a biopharmaceutical company based in Western Europe is aligned with the parent company’s strategy, focusing on technology investments related to oncology and infectious diseases. The firm has $150M under management and invests in the range of $1M – $10M per company. The Fund typically makes a first investment at Series A and currently aims to make 1-3 new equity investments a year.

The firm is mainly seeking digital health and healthcare IT investment opportunities at the pre-commercial or commercial stage that will either improve drug development or that will impact the patient journey (e.g., patient monitoring, digital therapeutics, clinical decision support systems) relating to oncology and infectious diseases.

The firm is very active and supportive of its portfolio companies. The Fund typically takes a board seat, and at times also an observer seat. The Fund is looking for management teams experienced in the domain of interest and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm headquartered in China invests in Chinese companies, or companies outside of China looking to enter the Chinese market. The firm invests solely in the life sciences, with most (~70%) of their investments in therapeutics companies, and the rest in medical device companies. For most of their investments, the firm participates in the first institutional round, investing between $7-15M, or the equivalent in RMB. The firm invests early, and in some cases acts as a venture builder as well as an investor.

The firm is primarily interested in therapeutics companies, with over half of their investments in this space. The firm is opportunistic in terms of indication, but is especially interested in new modalities within therapeutics, such as cell and gene therapies, or therapeutics in areas with high barriers to entry. For medical devices, the firm prefers technologies relating to surgical robotics and minimally invasive procedures.

The firm is an active investor, almost always taking a board seat and using their network to help the companies advance. This can come in the form of helping them round out their management team, or, if the company is looking to enter the China market, through joint ventures or help navigating the regulatory requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A seed-stage venture fund is focusing on the frontiers of the intersection of science and technology. The firm looks for companies that are changing the market standards through innovative approaches. The firm is interested in US-based companies and generally invests in seed-series A rounds, typically when less than $5m is being raised. The firm invests in pre-clinical/in development technologies but prefers there to be proof-of-concept data. For medical devices, the firm will consider devices in the 510k regulatory pathway. For all investments, the firm prefers that there is a deep data science or computational element to the technology being commercialized. The firm will generally invest between $250,000-1M, and will often connect companies to larger funds for later capital raises.

The firm is agnostic to sector and indication, and will also consider platform technologies. However, the firm is looking for companies that use DNA and cellular engineering technologies for diagnostics and therapeutics. Ideally, these technologies are also leveraging computation to accomplish their ends. The firm is not interested in standard therapeutics approaches such as small molecules. For medical devices, the firm is looking for devices that change the paradigms of care, solving an unmet need with a unique approach.

The firm does not require a board seat when investing. Rather, the firm will be as involved as necessary to help the company succeed, whether through personal intervention or through a connection to an external expert.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investing ecosystem that includes Accredited Angel Investors, Healthcare Systems, and Corporate Venture Investors focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance.

The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials.

While a management team must be in place, the firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of a large conglomerate with several global offices has two sites in the US is actively seeking new investment opportunities. In 2021, the firm raised a dedicated life science fund to invest in therapeutic and bioprocessing companies with flexibility of entering at different stages of development. The investment size varies depending on the opportunity. The firm is actively seeking new investment opportunities globally.

The firm will make new investments from both traditional funds and the new life science fund. The traditional funds invest in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The new life science fund is interested in therapeutics, particularly gene therapy, ADC technologies, RNA delivery platform technologies, and bioprocessing business that support these strategic areas of interest.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.